公开(公告)号：CR10656A

公开(公告)日：2009-05-22

申请号：CR10656

申请日：2009-03-06

Applicant: ABBOTT LAB

Inventor： WU CHENGBIN ,  DIXON RICHARD W ,  BELK JONATHAN P ,  YING HUA ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  HINTON PAUL ,  KUMAR SHANKAR ,  MELIM TERRY L ,  CHEN YAN

IPC: C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N1/15 ,  C12N1/16 ,  C12N1/21 ,  C12N5/00 ,  C12N5/04 ,  C12P21/00

Abstract: Proteinas de union a IL-13. Especificamente, la invencion se relaciona con anticuerpos que son quimericos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIIL-13 in vitro e in vivo. Un anticuerpo de la invencion puede ser un anticuerpo de longitud completa o una porcion de union al antigeno del mismo.

公开(公告)号：CA2620223A1

公开(公告)日：2007-03-08

申请号：CA2620223

申请日：2006-09-01

Applicant: ABBOTT LAB

Inventor： MORYTKO MICHAEL J ,  FRANK KRISTINE E ,  BETSCHMANN PATRICK ,  HIRST GAVIN C ,  CALDERWOOD DAVID J ,  DIXON RICHARD W ,  BREINLINGER ERIC C

IPC: A01N43/50

Abstract: The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I), wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

公开(公告)号：BRPI0716438A2

公开(公告)日：2014-03-04

申请号：BRPI0716438

申请日：2007-09-07

Applicant: ABBOTT LAB

Inventor： WU CHENGBIN ,  DIXON RICHARD W ,  BELK JONATHAN P ,  YING HUA ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  HINTON PAUL R ,  KUMAR SHANKAR ,  MELIN TERRY L ,  CHEN YAN

IPC: C12P21/08 ,  C07H21/00

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

公开(公告)号：NZ599144A

公开(公告)日：2013-10-25

申请号：NZ59914407

申请日：2007-09-07

Applicant: ABBOTT LAB

Inventor： WU CHENGBIN ,  DIXON RICHARD W ,  BELK JONATHAN P ,  YING HUA ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  HINTON PAUL R ,  KUMAR SHANKAR ,  MELIM TERRY L ,  CHEN YAN

IPC: C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/04 ,  C12P21/08

Abstract: 599144 Disclosed is a binding protein that possesses an antigen binding domain, said binding protein capable of binding IL-13, said antigen binding domain comprising six CDRs: CDR-H1 (TSDMGVD), CDR-H2 (HIWWDDVKRYNPALKS), CDR-H3 (TVSSGYIYYAMDY), CDR-L1 (RASQDIRNYLN), CDR-L2 (YTSKLHS or YTSMKPR), and CDR-L3 (QQGNTLPLT or QQGLTPPLT).

公开(公告)号：CR20130155A

公开(公告)日：2013-05-23

申请号：CR20130155

申请日：2013-04-03

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/00

Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.

公开(公告)号：CR20130149A

公开(公告)日：2013-05-23

申请号：CR20130149

申请日：2013-04-03

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/00

Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.

公开(公告)号：AU2006252098B2

公开(公告)日：2011-02-24

申请号：AU2006252098

申请日：2006-12-18

Applicant: ABBOTT LAB

Inventor： MANKOVICH JOHN ,  GHAYUR TARIQ ,  SHORROCK CELIA ELIZABETH ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH ,  SALFELD JOCHEN ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  ROGUSKA MIKE ,  DIXON RICHARD W

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：NO20091411L

公开(公告)日：2009-05-22

申请号：NO20091411

申请日：2009-04-07

Applicant: ABBOTT LAB

Inventor： HINTON PAUL R ,  BELK JONATHAN P ,  DIXON RICHARD W ,  KUMAR SHANKAR ,  WU CHENGBIN ,  YING HUA ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  MELIM TERRY L ,  CHEN YAN

IPC: C07K16/28 ,  A61K39/395 ,  A61P37/00 ,  C07K16/46 ,  C12N5/06 ,  C12N5/10 ,  C12N15/13 ,  C12P21/08

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

公开(公告)号：MX2009002554A

公开(公告)日：2009-03-20

申请号：MX2009002554

申请日：2007-09-07

Applicant: ABBOTT LAB

Inventor： HINTON PAUL R ,  DIXON RICHARD W ,  BELK JONATHAN P ,  KUMAR SHANKAR ,  WU CHENGBIN ,  ARGIRIADI MARIA A ,  YING HUA ,  CUFF CAROLYN A ,  MELIM TERRY L ,  CHEN YAN

IPC: C07K14/00 ,  C07H21/00 ,  C07K16/00 ,  C12N1/00 ,  C12N5/00 ,  C12P21/00

Abstract: La presente invención comprende proteínas de enlace lL 13. Específicamente la presente invención se refiere a anticuerpos que son anticuerpos quiméricos, injertados con CDR y humanizados. Los anticuerpos preferidos tienen alta afinidad para hlL-13 y neutralizan la actividad hlL-13 in vitro e in vivo. Un anticuerpo de la presente invención puede ser un anticuerpo de longitud total o una parte de enlace de antígeno el mismo. También se proporciona un método para utilizar los anticuerpos de la presente invención. Los anticuerpos o partes de anticuerpo de la presente invención son útiles para detectar hlL-13 o para inhibir la actividad de hlL-13, por ejemplo en un sujeto humano que padece de un trastorno en el cual la actividad de hTL-13 es perjudicial.

公开(公告)号：AU2007351514A1

公开(公告)日：2008-10-23

申请号：AU2007351514

申请日：2007-09-07

Applicant: ABBOTT LAB

Inventor： KUMAR SHANKAR ,  CHEN YAN ,  BELK JONATHAN P ,  WU CHENGBIN ,  DIXON RICHARD W ,  ARGIRIADI MARIA A ,  CUFF CAROLYN A ,  YING HUA ,  MELIM TERRY L ,  HINTON PAUL R

IPC: C07K14/00 ,  C07H21/00 ,  C07K16/00 ,  C12N1/00 ,  C12N1/15 ,  C12N1/16 ,  C12N1/21 ,  C12N5/00 ,  C12N5/04 ,  C12N5/06 ,  C12P21/00

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.